News from astrazeneca A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 10, 2018, 16:45 ET Forxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark

Fewer MACE events observed with Forxiga vs. placebo, but this finding did not reach statistical significance No imbalance in amputations, fractures, bladder cancer or Fournier's gangrene with Forxiga ...


Sep 25, 2018, 12:58 ET Imfinzi® (durvalumab) is the First Immunotherapy to Demonstrate Significant Overall Survival Benefits in Unresectable, Stage III Non-Small Cell Lung

Phase III PACIFIC data presented at the IASLC 2018 World Conference on Lung Cancer in Toronto shows 32 per cent reduced risk of death for patients treated with Imfinzi compared to standard of care...


Jul 12, 2018, 07:59 ET Health Canada Approves Tagrisso® (osimertinib) as First-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer

Pivotal FLAURA study demonstrated 18.9 months median progression-free survival for patients receiving Tagrisso versus 10.2 months compared with earlier generation EGFR tyrosine kinase inhibitors...


May 10, 2018, 07:59 ET Lynparza® (olaparib) Receives New Indication for BRCA-Mutated Metastatic Breast Cancer

Lynparza has been shown to reduce the risk of disease progression or death by 42 per cent compared to standard of care chemotherapy.i MISSISSAUGA, May 10, 2018 /CNW/ - AstraZeneca today announced...


May 09, 2018, 07:59 ET First and Only Immuno-Oncology Treatment, Imfinzi® (durvalumab), for Stage III, Unresectable Non-Small Cell Lung Cancer Now Approved in Canada

Patients receiving Imfinzi in the PACIFIC clinical trial lived for nearly one year without their disease progressing versus placebo MISSISSAUGA, ON, May 9, 2018 /CNW/ - AstraZeneca Canada today...


Nov 06, 2017, 07:59 ET Health Canada Approves IMFINZI® (durvalumab) for Previously Treated Patients with Advanced Bladder Cancer

Approval granted based on promising tumour response rate and duration of response MISSISSAUGA, ON, Nov. 6, 2017 /CNW/ - AstraZeneca Canada today announced that Health Canada has approved Imfinzi®...


Jul 27, 2017, 07:00 ET Valeant Announces U.S. Launch of SILIQ™ (brodalumab) Injection

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced the launch of SILIQ™ (brodalumab) Injection during the Summer American Academy of Dermatology (AAD) meeting taking ...


Oct 04, 2016, 02:05 ET Aralez to Acquire From AstraZeneca U.S. Rights to Beta Blocker Toprol-XL®

Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced it will acquire the U.S. rights to Toprol-XL® (metoprolol succinate) and its...


Jul 01, 2016, 02:00 ET Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX:VRX) ("Valeant") today announced that its affiliate and AstraZeneca (LSE/SSE/NYSE: AZN) have amended Valeant's license for brodalumab,...


Jun 09, 2016, 17:40 ET Valeant To Participate In FDA Advisory Committee Meeting On July 19

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced that it has received notification from the U.S. Food and Drug Administration (FDA)...


Apr 08, 2016, 07:00 ET Eli Lilly and Company and AstraZeneca Announce Continuation of Pivotal Clinical Trial for People with Early Alzheimer's Disease

Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced that AMARANTH, a Phase 2/3 study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a...


Sep 01, 2015, 02:00 ET Valeant And AstraZeneca To Partner On Brodalumab

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its affiliate has entered into a collaboration agreement with AstraZeneca under which Valeant was granted an...


Apr 17, 2015, 10:30 ET "Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC

ASSESS shows plasma circulating tumour DNA (ctDNA) testing for EGFR mutation is a viable alternative to tumour biopsy IGNITE supports value of EGFR mutation testing in all patients with advanced...


Jun 19, 2014, 18:41 ET Data Published In The New England Journal Of Medicine Demonstrate Naloxegol Improved Opioid-Induced Constipation In Chronic Pain Patients

LONDON, June 19, 2014 /CNW/ - AstraZeneca today announced that the New England Journal of Medicine (NEJM) has published results of two pivotal Phase III studies – KODIAC-4 and KODIAC-5 of naloxegol,...


May 31, 2014, 09:40 ET Investigational Drug AZD9291 Shows Clinical Responses in Patients With Advanced NSCLC Who Have Previously Failed on Established EGFR TKIs

CHICAGO, May 31, 2014 /CNW/ - Data from the ongoing Phase I AURA study in patients with epidermal growth factor receptor mutation positive (EGFRm+), advanced non-small cell lung cancer (NSCLC),...


Mar 18, 2013, 16:19 ET Compromising the Ability of Quebec Physicians to Effectively Treat Their Patients: AstraZeneca Responds to Quebec's Prescription Medication Price Cap

Quebec's recent decision to introduce a maximum price for one drug class will lead to public drug plan patients receiving the cheapest drugs in that class, even if their doctor has prescribed a...


Sep 22, 2010, 17:00 ET Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates
Positive Response in Rheumatoid Arthritis Patients

- Phase II Study Published in the New England Journal of Medicine LONDON and SAN FRANCISCO, Sept. 22 /CNW/ - AstraZeneca's (LSE: AZN) new oral syk inhibitor, fostamatinib (R788), recently in-licensed ...


Sep 20, 2010, 05:59 ET 24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved
Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults

STOCKHOLM, Sept. 20 /CNW/ - Bristol-Myers Squibb Company (NYSE: BMY)(http://www.bms.com) and AstraZeneca (NYSE: AZN)(http://www.astrazeneca-us.com) today announced results from a randomized, double...


Jun 26, 2010, 14:45 ET Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic
Control In Patients With Type 2 Diabetes Inadequately Controlled With

/NOT FOR US MEDIA/ ORLANDO, FL, June 26 /CNW/ - Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the...


Jun 26, 2010, 10:00 ET 52-Week Study Finds ONGLYZA(TM) (saxagliptin) When Added To Metformin Was
Non-Inferior To Titrated Glipizide When Added To Metformin In

/NOT FOR US MEDIA/ ORLANDO, FL, June 26 /CNW/ - Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a 52-week Phase 3b study in adults with type 2...


Jun 26, 2010, 09:30 ET ONGLYZA(TM) (saxagliptin) With Metformin As Initial Combination Therapy
Provided 76-Week Long-Term Glycemic Control In Treatment-Naive Adults

/NOT FOR US MEDIA/ ORLANDO, FL, June 26 /CNW/ - Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM)...


Apr 27, 2010, 02:01 ET CRESTOR(TM) Gains New EU Indication to Prevent Major Cardiovascular Events in
High Risk Patients

CRESTOR(TM) (rosuvastatin) has been approved in nineteen countries within the EU for the prevention of major cardiovascular events in patients who are at high risk* of having a first cardiovascular...


Mar 16, 2010, 09:00 ET Targeted approach represents paradigm shift in the diagnosis and treatment of
non-small cell lung cancer (NSCLC)

With a recent Health Canada approval for IRESSA(R), Canadian lung cancer patients can now be tested for EGFR mutation status and be treated with a more effective and better tolerated alternative to...